For Publishers
DiscoveryMetadataPeer reviewHostingPublishing
For Researchers
JoinPublishReviewCollect
Register
Blog
About
Search
Advanced search
My ScienceOpen
Search
For Publishers
For Researchers
Blog
About
26
views
0
references
 Top references
cited by
0
    
0 reviews
 Review
0
comments
 Comment
0
recommends
+1 Recommend
1 collections
    0
    shares
      1,029
      similar
       All similar

      Call for Papers: Green Renal Replacement Therapy: Caring for the Environment

      Submit here before December 31, 2024

      About Blood Purification: 2.2 Impact Factor I 5.8 CiteScore I 0.782 Scimago Journal & Country Rank (SJR)

      • Record: found
      • Abstract: found
      • Article: found

      Depressor Mechanism of Enalapril in Rats Made Hypertensive by Norepinephrine or Vasopressin

      research-article

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          We evaluated the antihypertensive mechanism of enalapril, a long-lasting inhibitor of angiotensin-converting enzyme, in rats made hypertensive by chronic infusion of norepinephrine or vasopressin. The hypertensive effect of norepinephrine (1.8 mg/kg/day intraperitoneal (i.p.)) or vasopressin (7.2 U/kg/day i.p.) was completely abolished by simultaneous administration of enalapril (6 mg/kg/day i.p.). The antihypertensive effect of enalapril was not reversed by simultaneous administration of subpressor doses of angiotensin II (36 and 100 μg/kg/day i.p.). However, the hypertensive effects of angiotensin II at pressor doses (600 and 900 μg/kg/day i. p.) in enalapril-infused rats were not different from those in vehicle-infused rats. These results indicate that the hypotensive effect of enalapril may in part depend on a reduced sensitivity of the vasculature to norepinephrine and vasopressin, independent of inhibition of angiotensin II formation.

          Related collections

          Author and article information

          Journal
          Journal ID (publisher-id): NEF
          Journal ID (nlm-ta): Nephron
          Journal ID (doi): 10.1159/issn.1660-8151
          Title: Nephron
          Publisher: S. Karger AG
          ISBN: 978-3-8055-5180-9
          ISBN: 978-3-318-01967-4
          ISSN (Print): 1660-8151
          ISSN (Electronic): 2235-3186
          Publication date Subscription-year: 1990
          Publication date (Print): 1990
          Publication date (Electronic): 16 December 2008
          Volume: 55
          Issue: Suppl 1
          Pages: 81-84
          Affiliations
          aSecond Department of Internal Medicine, Tohoku University School of Medicine, Sendai; bDepartment of Clinical Biology and Hormonal Regulation, Tohoku University School of Medicine, Sendai; cDepartment of Medicine, Hanamaki General Hospital, Hanamaki, Japan
          Article
          Publisher ID: 186042 Other ID: Nephron 1990;55:81–84
          DOI: 10.1159/000186042
          PubMed ID: 2345595
          SO-VID: 300d25b9-2c96-4c17-8260-9035799e3c4c
          Copyright © © 1990 S. Karger AG, Basel
          License:

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          History
          Page count
          Pages: 4
          Categories
          Subject: Poster Session

          ScienceOpen disciplines: Cardiovascular Medicine,Nephrology
          Keywords: Angiotensin II generation,Angiotensin-converting enzyme inhibitors,Vasopressin-induced hypertension,Norepinephrine-induced hypertension
          Data availability:
          ScienceOpen disciplines: Cardiovascular Medicine, Nephrology
          Keywords: Angiotensin II generation, Angiotensin-converting enzyme inhibitors, Vasopressin-induced hypertension, Norepinephrine-induced hypertension

          Comments

          Comment on this article